HER2

HER2 is a protein that promotes the growth of cells, and in some cases, it can contribute to the development of Breast cancer and other types of Cancer. The National Cancer Institute and the American Cancer Society have conducted extensive research on HER2, which is also known as ERBB2 or NEU. The Food and Drug Administration has approved several treatments that target HER2, including Trastuzumab and Pertuzumab, which are used in combination with Chemotherapy and other therapies, such as Radiation therapy at institutions like the Memorial Sloan Kettering Cancer Center and the University of Texas MD Anderson Cancer Center.

Introduction to HER2

HER2 is a member of the Epidermal growth factor receptor family, which includes EGFR, ERBB3, and ERBB4. The Human Genome Organisation and the National Institutes of Health have studied the role of HER2 in cell growth and Carcinogenesis, which is also a focus of research at the Stanford University School of Medicine and the Harvard Medical School. The European Organisation for Research and Treatment of Cancer and the American Association for Cancer Research have also investigated the relationship between HER2 and other Biomarkers, such as Estrogen receptor and Progesterone receptor, which are used to guide treatment decisions at hospitals like the Massachusetts General Hospital and the University of California, San Francisco.

Structure and Function

The structure of HER2 is similar to that of other Receptor tyrosine kinases, with an extracellular domain, a transmembrane domain, and an intracellular domain, which is also a feature of Insulin receptor and Platelet-derived growth factor receptor. The European Molecular Biology Laboratory and the National Center for Biotechnology Information have studied the crystal structure of HER2, which has provided insights into its function and interactions with other proteins, such as Grb2 and Shc1, which are involved in Signal transduction pathways, including the Ras pathway and the PI3K/AKT pathway. Researchers at the University of Cambridge and the University of Oxford have also investigated the role of HER2 in Cell signaling and Cell proliferation, which is a key aspect of Cancer biology.

Clinical Significance

HER2 is overexpressed in approximately 20% of Breast cancer cases, which is associated with a poorer Prognosis and reduced Survival rate, according to studies published in the Journal of Clinical Oncology and the New England Journal of Medicine. The American Society of Clinical Oncology and the European Society for Medical Oncology have developed guidelines for the diagnosis and treatment of HER2-positive breast cancer, which often involves a combination of Surgery, Chemotherapy, and Targeted therapy with drugs like Lapatinib and Neratinib, which are used at cancer centers like the Dana-Farber Cancer Institute and the Fred Hutchinson Cancer Research Center. Researchers at the Johns Hopkins University and the University of Chicago have also investigated the role of HER2 in other types of cancer, including Ovarian cancer and Stomach cancer.

Diagnosis and Testing

The diagnosis of HER2-positive breast cancer typically involves a combination of Immunohistochemistry and Fluorescence in situ hybridization (FISH) testing, which is performed at laboratories like the Mayo Clinic and the Cleveland Clinic. The College of American Pathologists and the American Society for Clinical Pathology have developed guidelines for HER2 testing, which is used to guide treatment decisions and predict response to therapy, including Hormone therapy and Immunotherapy with drugs like Pembrolizumab and Atezolizumab, which are used at hospitals like the University of Pennsylvania Health System and the Washington University School of Medicine.

Therapeutic Targeting

HER2 is a key target for cancer therapy, with several drugs approved for the treatment of HER2-positive breast cancer, including Trastuzumab, Pertuzumab, and Ado-trastuzumab emtansine, which are used in combination with Chemotherapy and other therapies, such as Radiation therapy at institutions like the Memorial Sloan Kettering Cancer Center and the University of Texas MD Anderson Cancer Center. Researchers at the Stanford University School of Medicine and the Harvard Medical School have also investigated the use of HER2-targeted therapies in combination with other treatments, such as PARP inhibitors and CDK4/6 inhibitors, which are used at cancer centers like the Dana-Farber Cancer Institute and the Fred Hutchinson Cancer Research Center.

Prognosis and Outcomes

The prognosis for patients with HER2-positive breast cancer has improved significantly in recent years, thanks to the development of effective targeted therapies, according to studies published in the Journal of Clinical Oncology and the New England Journal of Medicine. The American Cancer Society and the National Cancer Institute have reported improved Survival rates and reduced Mortality rates for patients with HER2-positive breast cancer, which is also a focus of research at the University of Cambridge and the University of Oxford. Researchers at the Johns Hopkins University and the University of Chicago have also investigated the role of HER2 in predicting response to therapy and guiding treatment decisions, which is a key aspect of Personalized medicine and Precision medicine at hospitals like the Massachusetts General Hospital and the University of California, San Francisco. Category:Cancer